Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study^†

References

• Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987–1996.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803.
   PubMed Web of Science ®Google Scholar
• Bernal T, Martinez-Camblor P, Sanchez-Garcia J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29(9):1875–1881.
   PubMed Web of Science ®Google Scholar
• Gangat N, Patnaik MM, Begna K, et al. Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer J. 2016;6(4):e414–e414.
   PubMedGoogle Scholar
• Al-Kali A, Zblewski D, Bartley AC, et al. Outcome of myelodysplastic syndromes over time in the US: A National Cancer Data Base Study from 2004–2013. Blood. 2016;128(22):3604.
   Google Scholar
• Zeidan AM, Wang R, Gross CP, et al. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leuk Lymphoma. 2017;58(4):982–985.
   PubMed Web of Science ®Google Scholar
• Dinmohamed AG, van Norden Y, Visser O, et al. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Leukemia. 2015;29(12):2449.
   PubMed Web of Science ®Google Scholar
• Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–2726.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Wang R, Davidoff AJ, et al. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. Cancer. 2016;122(10):1598–1607.
   PubMed Web of Science ®Google Scholar
• Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med. Care. 1998;36(1):8–27.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Gardner LD, Zuckerman IH, et al. Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Med. Care. 2014;52(6):500–510.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Zuckerman IH, Pandya N, et al. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J. Geriatr. Oncol. 2013;4(2):157–165.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, Hu X, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131(7):818–821.
   PubMed Web of Science ®Google Scholar
• Santini V. How I treat MDS after hypomethylating agent failure. Blood. 2019;133(6):521–529.
   PubMed Web of Science ®Google Scholar
• Grinblatt DL, Sekeres MA, Komrokji RS, et al. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA® registry. Leuk Lymphoma. 2015;56(4):887–895.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542–1551.
   PubMedGoogle Scholar
• Ma X, Steensma DP, Scott BL, et al. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ Open. 2018;8(7):e019955–e019955.
   Web of Science ®Google Scholar
• Harris KM, Remler DK. Who is the marginal patient? Understanding instrumental variables estimates of treatment effects. Health Serv. Res. 1998;33(5 Pt 1):1337–1360.
   PubMed Web of Science ®Google Scholar
• Ertefaie A, Small DS, Flory JH, et al. A tutorial on the use of instrumental variables in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(4):357–367.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30(3):649–657.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Othus M, List AF, et al. Randomized Phase II Study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35(24):2745–2753.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175(5):829–840.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(1):60–87.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
   PubMed Web of Science ®Google Scholar
• Benton CB, Khan M, Sallman D, et al. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018;93(10):1245–1253.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, DeVeaux M, et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J. 2018;8(6):55.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Hu X, Zhu W, et al. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leuk Lymphoma. 2019;1–12. DOI:10.1080/10428194.2019.1663423. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. JCO. 2006;24(24):3895–3903.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011;117(12):2697–2702.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, Sekeres MA, et al. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer. 2017;123(19):3662–3672.
   PubMed Web of Science ®Google Scholar